Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.20USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
47,098
52-wk High
$3.06
52-wk Low
$1.13

Latest Key Developments (Source: Significant Developments)

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article

Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cellectar Biosciences Inc ::Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma.  Full Article

Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors.Japanese patent office granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125​.  Full Article

Cellectar Biosciences and Pierre Fabre extend collaboration
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates.Cellectar Biosciences - ‍aim of extension is to further evaluate synergistic effects observed when Cellectar's phospholipid ethers are combined with Pierre Fabre's novel cytotoxic payloads​.Cellectar Biosciences - ‍program teams will continue to evaluate the new PDC compounds.  Full Article

Cellectar Biosciences says USPTO grants patent for Paclitaxel PDC
Monday, 12 Dec 2016 

Cellectar Biosciences Inc : Cellectar Biosciences announces USPTO grants patent for Paclitaxel PDC; provides additional patent protection for select solid tumors through 2035 .Cellectar Biosciences - plan to initiate a Phase II trial for CLR 131 in patients with relapsed or refractory multiple myeloma and select hematologic malignancies in early 2017.  Full Article

Cellectar Biosciences files for mixed shelf of upto $10 mln
Friday, 28 Oct 2016 

Cellectar Biosciences Inc - :Files for a mixed shelf of upto $10 million - SEC filing.  Full Article

Cellectar Biosciences announces recent key accomplishments, Q2 results
Thursday, 11 Aug 2016 

Cellectar Biosciences Inc : Cellectar Biosciences announces recent key accomplishments and second quarter 2016 financial results . Cellectar Biosciences Inc says company expects that additional capital will be required to complete its planned clinical and preclinical development .Cellectar Biosciences Inc says company estimates that its available cash and cash equivalents should fund its planned operations into Q1 of 2017.  Full Article

Cellectar Biosciences files for resale of 300,006 shares
Friday, 17 Jun 2016 

Cellectar Biosciences Inc :Files for resale of 300,006 shares of common stock offered by selling stockholders - SEC filing.  Full Article

Cellectar biosciences says can fund ops into Q1 2017
Thursday, 12 May 2016 

: Cellectar biosciences inc says estimates that its available cash and cash equivalents should fund its planned operations into q1 of 2017 .Cellectar biosciences announces first quarter 2016 financial results.  Full Article

BRIEF-Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131

* CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131